Schizophrenia Clinical Trials in Richmond, Virginia

5 studies are recruiting for schizophrenia in Richmond, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

    This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

    Stage
    Phase 4
    Ages
    18 and older
    Site
    Neurocrine Clinical Site, Richmond, Virginia
    Locations
    19 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT07105111 on ClinicalTrials.gov

  2. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

    The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.

    Stage
    Phase 3
    Ages
    13 to 17
    Site
    Local Institution - 0050, Richmond, Virginia
    Locations
    38 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07288567 on ClinicalTrials.gov

  3. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

    Stage
    Phase 3
    Ages
    5 to 17
    Site
    Virginia Commonwealth University, Richmond, Virginia
    Locations
    64 in total
    Run by
    Intra-Cellular Therapies, Inc.

    See if you can join NCT06229210 on ClinicalTrials.gov

  4. A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

    The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively

    Stage
    Phase 3
    Ages
    5 to 17
    Site
    Local Institution - 0050, Richmond, Virginia
    Locations
    91 in total
    Run by
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company

    See if you can join NCT07424404 on ClinicalTrials.gov

  5. Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

    To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine

    Stage
    Phase 3
    Ages
    10 to 17
    Site
    Alkermes Investigational Site, Richmond, Virginia
    Locations
    47 in total
    Run by
    Alkermes, Inc.

    See if you can join NCT05303064 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.